VIDEO: Biomarkers, novel treatments among highlights in prostate cancer at ASCO

CHICAGO — In this video, Andre Kydd, MD, PhD, discusses highlights in the field of prostate cancer, including biomarkers of response in treatment and data on new classes of therapeutic agents, presented at ASCO Annual Meeting.
“We look forward to providing more information on ways that these may ultimately start to effect clinical practice in the coming months and years,” Kydd, assistant professor of genitourinary medical oncology at Fox Chase Cancer Center, told Healio.

VIDEO: Giredestrant improves breast cancer survival, regardless of menopause status

CHICAGO — In this video, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial, which assessed efficacy and safety of adjuvant giredestrant in premenopausal vs. postmenopausal women with breast cancer.
Findings from the study, which compared giredestrant (Genentech, Roche) with standard-of-care endocrine therapy in ER-positive, HER2-negative early breast cancer, were presented at ASCO Annual Meeting.
Regardless of menopause status, giredestrant improved survival for women with breast cancer.
“With the approval of adjuvant abemaciclib (Verzenio, Eli Lilly & Co.) and

New button battery technology shows promise, but swallowing remains an emergency

A recently released child-safety battery designed to reduce the danger from accidental ingestion is showing significant promise, but medical professionals should not alter their management protocols yet. In the first peer-reviewed scientific assessment of the recently commercialized Energizer Ultimate Child Shield, researchers found that the titanium-based lithium coin-cell battery, designed to protect the esophagus, can reduce the severity of tissue injury.

Behavioral therapy can be just as effective as medication for Tourette syndrome, says researcher

Behavioral therapy is just as effective as medication for Tourette syndrome. This is the finding of doctoral research conducted by clinical psychologist Jolande van de Griendt, who will receive her Ph.D. from Radboud University on July 3, 2026. "Medication is still often the first step in treating a tic disorder. But for many people, it's a great relief to be able to do something about their symptoms without taking pills."